11 articles
Safety and side effects, separated from the headlines
A labeled warning and a measured rate are different objects, and most reporting on these drugs runs them together. These articles keep them apart: what each label requires be disclosed, what the trial record actually counted, where the human evidence disagrees with itself, and which symptoms mean a same-day call to a clinician rather than more reading.
Is Compounded Tirzepatide Safe? What FDA Has Actually Reported
FDA has never reviewed compounded tirzepatide for safety, effectiveness or quality. That is a fact about regulatory review, not a finding of harm. Here is what the agency has actually reported, what separates a 503A pharmacy from a 503B facility, and what nobody can tell you.
11 min read · 9 citationsCompounded Tirzepatide Side Effects: The Drug, and the Vial
Most compounded tirzepatide side effects are tirzepatide side effects, documented in the approved product's label and trials. A smaller set comes from the preparation: a pharmacy-set concentration, added ingredients, and an adverse-event pathway that may never count your report.
10 min read · 7 citationsTirzepatide Long-Term Side Effects: Where the Evidence Stops
The longest published randomized tirzepatide treatment in obesity is 176 weeks, and the cardiovascular trial ran a median of 46.9 months. This separates what the approved label warns about from what a trial actually counted, and says where the record ends.
11 min read · 11 citationsHow Long Do Semaglutide and Tirzepatide Side Effects Last?
What predicts side effects is where you are on the ladder, not how many weeks you have been taking it. Both labels place the nausea and diarrhea during escalation, and how long any single dose keeps working comes down to half-life: roughly seven days for semaglutide, roughly five for tirzepatide.
11 min read · 8 citationsGLP-1 Thyroid Cancer Risk: What the Boxed Warning Actually Says
A boxed warning about thyroid C-cell tumors sits on every semaglutide and tirzepatide label there is. It comes from rodent studies, the labels themselves say the human relevance is undetermined, and the human research published since does not agree with itself.
11 min read · 10 citationsGLP-1 Eye Risks: Diabetic Retinopathy and NAION Are Not the Same Thing
Two distinct eye questions get merged into one headline. Diabetic retinopathy complications are on the semaglutide label and trace to blood sugar falling fast; NAION is a separate optic-nerve signal that Europe labeled in June 2025 and US labeling still does not mention.
12 min read · 15 citationsGLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted
Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.
12 min read · 19 citationsGLP-1 Hair Loss and Muscle Loss: What Was Measured
Hair shedding and lean-mass loss both appear in the trial record, and both are mostly consequences of losing weight quickly rather than of the drug. That is reassuring about mechanism and not reassuring about outcome, and this holds both.
11 min read · 15 citationsGLP-1s and Hormonal Birth Control: Which Labels Carry the Warning
The labeled interaction between a GLP-1 and the contraceptive pill belongs to tirzepatide alone. Mounjaro and Zepbound set a four-week window after starting and after every dose increase; the three semaglutide labels carry no such advisory. We read all five to establish which is which.
9 min read · 8 citationsGLP-1s, Pregnancy and Trying to Conceive: What the Labels Say
If you are pregnant or might be, this is a conversation with a clinician. What this sets out is the text behind it: each label's own wording on pregnancy, on the interval before a planned one, and on breastfeeding, plus where the human evidence is genuinely thin.
11 min read · 10 citationsWhat Happens When You Stop a GLP-1: What the Withdrawal Trials Measured
Three randomized trials took semaglutide or tirzepatide away from people who had lost weight on it and measured what came back: the weight, and the cardiometabolic gains with it.
11 min read · 12 citations